{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:54:43Z","timestamp":1790736883659,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05041-y","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:44:35Z","timestamp":1783345475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term efficacy of increasing 0.01% atropine administration frequency in controlling myopia progression in adolescents"],"prefix":"10.1186","volume":"26","author":[{"given":"Jing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"5041_CR1","doi-asserted-by":"publisher","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.","DOI":"10.1016\/j.ophtha.2016.01.006"},{"issue":"1","key":"5041_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029. Epub 2018 Jul 6. PMID: 30514630.","journal-title":"Ophthalmology"},{"issue":"6","key":"5041_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624\u201330. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1091. PMID: 28494063; PMCID: PMC5710262.","journal-title":"JAMA Ophthalmol"},{"key":"5041_CR4","doi-asserted-by":"publisher","unstructured":"Huang J, Wen, Daizong, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children a network meta-analysis[J]. Ophthalmol. 2016;23(4):697\u2013708. https:\/\/doi.org\/10.1016\/j.ophtha.2015.11.010.","DOI":"10.1016\/j.ophtha.2015.11.010"},{"key":"5041_CR5","doi-asserted-by":"publisher","unstructured":"Holden BA, Fricke, Timothy R, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmol. 2016;123(5):1036\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006.","DOI":"10.1016\/j.ophtha.2016.01.006"},{"issue":"9","key":"5041_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","volume":"131","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, Chen LJ, Pang CP, Yam JC. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Ophthalmology. 2024;131(9):1011\u201320. Epub 2024 Mar 16. PMID: 38494130.","journal-title":"Ophthalmology"},{"issue":"2","key":"5041_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016;123(2):391\u20139. Epub 2015 Aug 11. PMID: 26271839.","journal-title":"Ophthalmology"},{"issue":"1","key":"5041_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113\u201324. Epub 2018 Jul 6. PMID: 30514630.","journal-title":"Ophthalmology"},{"issue":"2","key":"5041_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ped4.70002","volume":"9","author":"L Li","year":"2025","unstructured":"Li L. Interpretation of expert consensus on the application of low-concentration atropine eye drops in the prevention and control of myopia in children and adolescents. Pediatr Investig. 2025;9(2):107\u201313. https:\/\/doi.org\/10.1002\/ped4.70002. PMID: 40539007; PMCID: PMC12175632.","journal-title":"Pediatr Investig"},{"key":"5041_CR10","doi-asserted-by":"publisher","unstructured":"Expert consensus on the application of axial length in myopia prevention and control management. (2023) [J]. Chin J Exp Ophthalmology. Jan 2024;42(1):1\u201311. https:\/\/doi.org\/10.3760\/cma.j.cn115989-20231010-00121.","DOI":"10.3760\/cma.j.cn115989-20231010-00121"},{"issue":"1","key":"5041_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12886-025-04020-z","volume":"25","author":"J Wang","year":"2025","unstructured":"Wang J, Zhou J. Relationship between the axial length\/corneal radius of curvature ratio and hyperopia reserve in preschool children aged 3\u20136 years. BMC Ophthalmol. 2025;25(1):198. https:\/\/doi.org\/10.1186\/s12886-025-04020-z. PMID: 40217488; PMCID: PMC11987429.","journal-title":"BMC Ophthalmol"},{"key":"5041_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40780-019-0154-2","volume":"5","author":"J Saito","year":"2019","unstructured":"Saito J, Imaizumi H, Yamatani A. Physical, chemical, and microbiological stability study of diluted atropine eye drops. J Pharm Health Care Sci. 2019;5:25. https:\/\/doi.org\/10.1186\/s40780-019-0154-2. PMID: 31844539; PMCID: PMC6894105.","journal-title":"J Pharm Health Care Sci"},{"issue":"4","key":"5041_CR13","first-page":"527","volume":"8","author":"HV Gimbel","year":"1973","unstructured":"Gimbel HV. The control of myopia with atropine. Can J Ophthalmol. 1973;8(4):527\u201332. PMID: 4751898.","journal-title":"Can J Ophthalmol"},{"issue":"11","key":"5041_CR14","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1021\/pr500558y","volume":"13","author":"VA Barathi","year":"2014","unstructured":"Barathi VA, Chaurasia SS, Poidinger M, Koh SK, Tian D, Ho C, Iuvone PM, Beuerman RW, Zhou L. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res. 2014;13(11):4647\u201358. https:\/\/doi.org\/10.1021\/pr500558y. Epub 2014 Oct 1. PMID: 25211393; PMCID: PMC4227558.","journal-title":"J Proteome Res"},{"issue":"6","key":"5041_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3760\/cma.j.cn115909-20220608-00235","volume":"24","author":"Expert Consensus on Application of Low-Concentration Atropine Eye Drops in the Prevention and Control of Myopia in Children and Adolescents","year":"2022","unstructured":"Expert Consensus on Application of Low-Concentration Atropine Eye Drops in the Prevention and Control of Myopia in Children and Adolescents. [J]. Chin J Optometry Ophthalmol Visual Sci 2022. 2022;24(6):401\u20139. https:\/\/doi.org\/10.3760\/cma.j.cn115909-20220608-00235.","journal-title":"Chin J Optometry Ophthalmol Visual Sci 2022"},{"key":"5041_CR16","doi-asserted-by":"publisher","first-page":"1227787","DOI":"10.3389\/fphar.2023.1227787","volume":"14","author":"P Hou","year":"2023","unstructured":"Hou P, Wu D, Nie Y, Wei H, Liu L, Yang G. Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis. Front Pharmacol. 2023;14:1227787. PMID: 37767401; PMCID: PMC10520549.","journal-title":"Front Pharmacol"},{"issue":"12","key":"5041_CR17","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062. Epub 2006 Sep 25. PMID: 16996612.","journal-title":"Ophthalmology"},{"issue":"2","key":"5041_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"issue":"5","key":"5041_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.62.5.3","volume":"62","author":"IG Morgan","year":"2021","unstructured":"Morgan IG, Wu PC, Ostrin LA, Tideman JWL, Yam JC, Lan W, Baraas RC, He X, Sankaridurg P, Saw SM, French AN, Rose KA, Guggenheim JA. IMI Risk Factors for Myopia. Invest Ophthalmol Vis Sci. 2021;62(5):3. https:\/\/doi.org\/10.1167\/iovs.62.5.3. PMID: 33909035; PMCID: PMC8083079.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"17","key":"5041_CR20","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/s41433-025-03964-2","volume":"39","author":"M He","year":"2025","unstructured":"He M, Zhang Z, Tong L, Liu L, Han D, Zhang H, Zhang S, Wang L, Bai Y, Du B, Wei R. Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial. Eye (Lond). 2025;39(17):3105\u201312. https:\/\/doi.org\/10.1038\/s41433-025-03964-2. Epub 2025 Oct 1. PMID: 41034350; PMCID: PMC12624075.","journal-title":"Eye (Lond)"},{"key":"5041_CR21","doi-asserted-by":"publisher","unstructured":"Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, Sankaridurg P, Saw SM, Trier K, Walline JJ, Wu PC, Wolffsohn JS. IMI - interventions myopia institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci. 2019;60(3):M106-M131. Erratum in: Invest Ophthalmol Vis Sci. 2019;60(5):1768. 10.1167\/iovs.18-25958a. PMID: 30817829. https:\/\/doi.org\/10.1167\/iovs.18-25958.","DOI":"10.1167\/iovs.18-25958"},{"key":"5041_CR22","doi-asserted-by":"publisher","unstructured":"He Meinan M, Baoyue Z, Ying, et al. Effects of short-term use of atropine with different concentrations and frequencies on eye safety in children [J]. Chin J Exp 0phthalmol, May 2023;41(5). https:\/\/doi.org\/10.3760\/cma.j.cn115989-20220519-00230.","DOI":"10.3760\/cma.j.cn115989-20220519-00230"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05041-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05041-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05041-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:58:40Z","timestamp":1790733520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05041-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5041"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05041-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Children\u2019s Hospital of Fudan University. Informed written consent was obtained from all patients. For the patients under 18 years old, informed consents were signed with their parents before the study. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"609"}}